We are live on ! Find out more
GTHX

G1 Therapeutics, Inc. Common Stock
GTHX

Delisted

GTHX was delisted on the 17th of September, 2024.

Back to rankings

114 hedge funds and large institutions have $541M invested in G1 Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 43 increasing their positions, 31 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 31

12% more call options, than puts

Call options by funds: $7.08M | Put options by funds: $6.33M

7% less capital invested

Capital invested by funds: $582M → $541M (-$40.3M)

7% less funds holding

Funds holding: 123 → 114 (-9)

45% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 20

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
114
Holders Change
-9
Holders Change %
-7.32%
% of All Funds
1.98%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
11
Increased
43
Reduced
31
Closed
20
Calls
$7.08M
Puts
$6.33M
Net Calls
+$749K
Net Calls Change
+$2.97M

Top Buyers

Rank Fund Capital Flow
1
Fisher Asset Management
Fisher Asset Management
Washington
+$20.3M
2
Morgan Stanley
Morgan Stanley
New York
+$7.46M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.55M
4
TCM
Tekla Capital Management
Massachusetts
+$5.17M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$5M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$17.1M
2
CLOS
Compagnie Lombard Odier SCmA
Switzerland
-$14.5M
3
Two Sigma Investments
Two Sigma Investments
New York
-$4.7M
4
Goldman Sachs
Goldman Sachs
New York
-$2.86M
5
MB
MPM BioImpact
Massachusetts
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
VOYA Investment Management
26
VOYA Investment Management
Georgia
$3.01M -$770K -34,655 -20%
RJA
27
Raymond James & Associates
Florida
$2.91M +$281K +12,628 +11%
Rafferty Asset Management
28
Rafferty Asset Management
New York
$2.65M -$490K -22,042 -15%
Ameriprise
29
Ameriprise
Minnesota
$2.54M +$939K +42,288 +58%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.52M -$354K -15,941 -12%
Wells Fargo
31
Wells Fargo
California
$2.12M +$402K +18,102 +23%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$1.77M -$1.17M -52,651 -39%
Swiss National Bank
33
Swiss National Bank
Switzerland
$1.42M – – –
GG
34
Golden Green
South Carolina
$1.31M +$38.9K +1,750 +3%
AA
35
ALPS Advisors
Colorado
$1.22M +$1.23M +55,417 New
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$1.19M +$58K +2,613 +5%
PP
37
PDT Partners
New York
$1.12M -$918K -41,312 -45%
CA
38
CHI Advisors
New York
$1.1M – – –
DekaBank Deutsche Girozentrale
39
DekaBank Deutsche Girozentrale
Germany
$1.06M – – –
BCM
40
Burrage Capital Management
Massachusetts
$1.05M -$1.55M -70,000 -59%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$1.01M -$77.7K -3,496 -7%
State of Wisconsin Investment Board
42
State of Wisconsin Investment Board
Wisconsin
$1.01M – – –
Citadel Advisors
43
Citadel Advisors
Florida
$924K -$761K -34,254 -45%
JAM
44
Jupiter Asset Management
United Kingdom
$906K +$917K +41,289 New
UBS AM
45
UBS AM
Illinois
$900K +$64.4K +2,899 +8%
SG Americas Securities
46
SG Americas Securities
New York
$885K -$110K -4,947 -11%
RJFSA
47
Raymond James Financial Services Advisors
Florida
$882K -$8.42K -379 -0.9%
BC
48
Birchview Capital
Vermont
$878K – – –
Massachusetts Financial Services
49
Massachusetts Financial Services
Massachusetts
$876K +$7.6K +342 +0.9%
Jane Street
50
Jane Street
New York
$870K -$1.78M -80,000 -67%
1
2
3 4 5

GTHX Hedge Fund Activity: Q2 2021 in Review

114 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q2 2021, worth a combined $541M — down 6.9% from $582M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of GTHX and 11 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 43 added.

The largest buyer was Fisher Asset Management, opening a new position worth an estimated $20.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.1M.

  • 114 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q2 2021, down from 123 in Q1 2021.
  • Funds reported $541M of G1 Therapeutics, Inc. Common Stock stock for Q2 2021, down 6.9% quarter-over-quarter.
  • 11 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q2 2021 and 20 closed out, a net change of -9 holders.
  • The largest G1 Therapeutics, Inc. Common Stock buyer in Q2 2021 was Fisher Asset Management, an estimated $20.3M added.
  • The largest G1 Therapeutics, Inc. Common Stock seller in Q2 2021 was T. Rowe Price Associates, an estimated $17.1M sold.

Based on aggregated 13F filings for Q2 2021.